±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1530  |  »Ø¸´: 3

yangxicshe

Ìú³æ (СÓÐÃûÆø)

[½»Á÷] ¡¾ÇóÖú¡¿ÈܼÁ·åºÍÒ©·å×ÜÊÇÖØµþÔÚÒ»ÆðÁË£¬Ó¦¸ÃÔõôµ÷Õû±ÈÀý£¿ ÒÑÓÐ3È˲ÎÓë

Á÷¶¯ÏàµÄ×î¼Ñ±ÈÀý
¸÷λ×ÊÉîÈËÊ¿£¬ÎÒÊÇHPLCµÄÐÂÊÖ£¬ÏÖÔÚÔÚ×ö¶àÎ÷»·ËصÄHPLCµÄ²â¶¨£¬ÔÚ365nmµÄ²¨³¤Ï£¬Á÷¶¯ÏàÊÇ0.01M²ÝËá-ÒÒëæ-¼×´¼£¬Ô­À´µÄ±ÈÀýÊÇ

50:35:15£¬µ«ÊÇÈܼÁ·åºÍÒ©·å×ÜÊÇÖØµþÔÚÒ»ÆðÁË£¬Ó¦¸ÃÔõôµ÷Õû±ÈÀý°¡£¿¼×´¼£¬ÒÒëæµÄÎüÊÕ²¨³¤ÓÖÊǶàÉÙÄØ£¿ÆÚÅλظ´£¡
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

dingjinglvde

ľ³æ (ÕýʽдÊÖ)

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
karl2100(½ð±Ò+1): ¶àлÌṩ£¡ 2011-03-11 19:48:21
ÈܼÁÈç¹ûÊÇÁ÷¶¯Ï࣬ÔÚ365nmÓ¦¸ÃûÓÐÎüÊÕ°¡
Èç¹ûÓз壬Ӧ¸ÃºÜС£¬³ö·åʱ¼äÒ²Ó¦¸ÃºÜÔçµÄ

USP33
ASSAY
•  Procedure
Mobile phase:  Transfer 2.72 g of monobasic potassium phosphate, 0.74 g of sodium hydroxide, 0.50 g of tetrabutylammonium hydrogen sulfate, and 0.40 g of edetate disodium to a 1000-mL volumetric flask. Add 850 mL of water, and stir to dissolve. Add 60 g of tertiary butyl alcohol with the aid of water, dilute with water to volume, and adjust with 1 N sodium hydroxide to a pH of 8.0 ¡À 0.1. Pass this solution through a filter having a porosity of 0.5 µm or finer, and degas before using. Decreasing the proportion of tertiary butyl alcohol results in a longer retention time of doxycycline and improved separation of doxycycline from the related compounds.
Diluent:  0.01 N hydrochloric acid
System suitability solution:  Prepare a solution of USP Doxycycline Hyclate RS in Diluent containing about 6 mg of doxycycline/mL. Transfer 5 mL of this solution to a 25-mL volumetric flask, heat on a steam bath for 60 min, and evaporate to dryness on a hot plate, taking care not to char the residue. Dissolve the residue in 0.01 N hydrochloric acid, dilute with Diluent to volume, and mix. Pass a portion of this solution through a filter having a porosity of 0.5 µm or finer, and use the filtrate. This solution contains a mixture of 4-epidoxycycline, 6-epidoxycycline, and doxycycline. When stored in a refrigerator, this solution may be used for 14 days.
[Note¡ªThroughout the following procedures, protect the Standard solution and the Sample solution from light. ]
Standard solution:  Transfer 12 mg of USP Doxycycline Hyclate RS, to a 10-mL volumetric flask, add 6 mL of Diluent, sonicate for about 5 min or until dissolved, and dilute with Diluent to volume.
Sample solution:  55 mg of Doxycycline in a 50-mL volumetric flask. Add 12 mL of 0.1 N hydrochloric acid, swirl to dissolve, and dilute with Diluent to volume. Filter through a filter of 0.5 µm or finer porosity.
Chromatographic system  
(See Chromatography 621, System Suitability.)
Mode:  LC
Detector:  UV 270 nm
Column:  4.6-mm ¡Á 25-cm; packing L21
Column temperature:  60 ¡À 1
Flow rate:  1 mL/min
Injection size:  20 µL
System suitability  
Sample:  System suitability solution and Standard solution
[Note¡ªThe relative retention times for 4-epidoxycycline (the main degradation product), 6-epidoxycycline, and doxycycline are 0.4, 0.7, and 1.0, respectively. ]
Suitability requirements  
Resolution:  NLT 3.0 between the 4-epidoxycycline peak and the doxycycline peak, System suitability solution
Tailing factor:  NMT 2.0, System suitability solution
Relative standard deviation:  NMT 2.0%, Standard solution
Analysis  
Samples:  Standard solution and Sample solution
Calculate the quantity of C22H24N2O8, in µg, in each mg of the Doxycycline taken:
Result = (rU/rS) ¡Á (CS/CU) ¡Á P
rU = = peak response from the Sample solution
rS = = peak response from the Standard solution
CS = = concentration of USP Doxycycline Hyclate RS in the Standard solution (mg/mL)
CU = = concentration of the Sample solution (mg/mL)
P = = designated potency of doxycycline (C22H24N2O8), of USP Doxycycline Hyclate RS (µg/mg)

Acceptance criteria:  NLT 880 µg/mg and NMT 980 µg/mg
2Â¥2011-03-11 17:18:54
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

cjl2fl

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
ÎÒ¾õµÃÓпÉÄÜÊDzÝËáµÄÎÊÌ⣬Êʵ±Ìá¸ß¼×´¼µÄ±ÈÀýÊÔÊÔ£¿
3Â¥2011-03-11 18:43:28
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xiaodu2007693

ľ³æ (ÖøÃûдÊÖ)

ҩѧ°æ~Áúè

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
ÈܼÁ·åÒ»°ã±È½Ï¿¿Ç°£¬Äã¿ÉÒÔ½µµÍÁ÷¶¯Ïà±ÈÀý£¬ÈÃÒ©ÎïÍùºóÍÏÒ»ÍÏ
»¶Ó­ÄúÀ´Ò©Ñ§°æ~
4Â¥2011-03-11 19:17:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ yangxicshe µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] µ÷¼Á +7 ²»·ê´º 2026-04-05 8/400 2026-04-05 23:34 by À´¿´Á÷ÐÇÓê10
[¿¼ÑÐ] 294Çóµ÷¼Á +4 Grey_Ey 2026-04-01 5/250 2026-04-05 23:05 by Grey_Ey
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸ÏÃÃÅ´óѧ£¬ÉúÎïÓëÒ½Ò©£¬×Ü·Ö272£¬±¾¿Æ211 +3 Electron1cc 2026-04-01 4/200 2026-04-05 20:24 by lys0704
[¿¼ÑÐ] 277Çóµ÷¼Á +5 ¿¼Ñе÷¼Álxh 2026-04-05 5/250 2026-04-05 19:03 by chy09050039
[¿¼ÑÐ] 282Çóµ÷¼Á +7 aaa³µÁ¾ 2026-04-02 11/550 2026-04-05 17:24 by yulian1987
[¿¼ÑÐ] 288Çóµ÷¼Á +7 ûÓдð°¸_ 2026-04-05 7/350 2026-04-05 17:01 by yulian1987
[¿¼ÑÐ] 328·Öµ÷¼Á +6 ÃÅmen 2026-04-04 6/300 2026-04-05 13:40 by imissbao
[¿¼ÑÐ] 270Çóµ÷¼Á +9 С½Üpp 2026-03-31 11/550 2026-04-05 11:02 by ·çÓêÎÞÇç
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +12 19123253302 2026-04-04 12/600 2026-04-05 08:08 by 544594351
[¿¼ÑÐ] 288»·¾³×¨Ë¶,Çóµ÷²ÄÁÏ·½Ïò +13 lllllos 2026-04-04 14/700 2026-04-04 23:34 by lqwchd
[¿¼ÑÐ] 359Çóµ÷¼Á +7 hhhhaaaa$ 2026-04-04 7/350 2026-04-04 18:49 by imissbao
[¿¼ÑÐ] 319Çóµ÷¼Á +4 ÐÇÐDz»Õ£ÑÛà¶ 2026-04-03 4/200 2026-04-04 16:25 by ÖзÉÔº¿Õ¹ÜѧԺÑ
[¿¼ÑÐ] 305Çóµ÷¼Á +3 77Qi 2026-04-03 3/150 2026-04-03 23:01 by qzxyhcsy
[¿¼ÑÐ] »¯¹¤Çóµ÷¼Á +11 ÀóÏã֥ʿҬÄÌ 2026-04-03 11/550 2026-04-03 22:06 by à£à£à£0119
[¿¼ÑÐ] Êý¶þÓ¢¶þ348Çóµ÷¼Á +4 hxdzj1 2026-04-03 5/250 2026-04-03 21:25 by zhq0425
[¿¼ÑÐ] 366Çóµ÷¼ÁÒ»Ö¾Ô¸¶«±±´óѧ +8 ÔËÆøÀ´µÃÈôÓÐËÆÎ 2026-04-02 8/400 2026-04-02 21:39 by dongzh2009
[¿¼ÑÐ] 26¿¼Ñе÷¼Á +4 Wnz.20030617 2026-04-01 5/250 2026-04-02 16:11 by 1939136013¹·×³
[¿¼ÑÐ] 0856³õÊÔ324·ÖÇóµ÷¼Á +6 ÏëÉÏѧÇóµ÷ 2026-04-01 6/300 2026-04-02 11:42 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] Çóµ÷¼Á +4 ͼ¼ø212 2026-03-30 5/250 2026-04-01 15:32 by ͼ¼ø212
[¿¼ÑÐ] 085601 329·Öµ÷¼Á +6 yzsa12 2026-03-31 6/300 2026-03-31 15:23 by yanflower7133
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û